1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides an overview of the Multiple Myeloma (Oncology) pipeline landscape.
Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Multiple Myeloma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 8, 10, 105, 118, 4, 10, 165, 29 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 19, 9, 32 and 8 molecules, respectively.
Multiple Myeloma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Multiple Myeloma (Kahler Disease) - Overview
- Multiple Myeloma (Kahler Disease) - Therapeutics Development
- Multiple Myeloma (Kahler Disease) - Therapeutics Assessment
- Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development
- Multiple Myeloma (Kahler Disease) - Drug Profiles
- Multiple Myeloma (Kahler Disease) - Dormant Projects
- Multiple Myeloma (Kahler Disease) - Discontinued Products
- Multiple Myeloma (Kahler Disease) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Aadi Bioscience Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by ABL Bio Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Acepodia Biotech Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Adicet Bio Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Agenus Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Allife Medical Science and Technology Co Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Allogene Therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Ambrx Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Antengene Corp, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Arcellx Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Momenta Pharmaceuticals Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Multitude therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Mustang Bio Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by SpecificiT Pharma Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by SpringWorks Therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Starton Therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Sunomix Therapeutics, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Suzhou Maximum Bio-tech Co Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by T-CURX GmbH, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by T-Knife GmbH, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by TaiGen Biotechnology Co Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Oncology Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Tmunity Therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Tolero Pharmaceuticals Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Triterpenoid Therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Ube Industries Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Vycellix Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by WindMIL Therapeutics Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Wugen Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan YZY Biopharma Co Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by XEME BioPharma Inc, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Xiangxue Life Sciences, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by XNK Therapeutics AB, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Zhengda Tianqing Pharmaceutical Group Co Ltd, H1 2020
- Multiple Myeloma (Kahler Disease) - Pipeline by Zovis Pharmaceuticals, H1 2020
- Multiple Myeloma (Kahler Disease) - Dormant Projects, H1 2020
- Multiple Myeloma (Kahler Disease) - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Multiple Myeloma (Kahler Disease), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4SC AG
- A. Menarini Industrie Farmaceutiche Riunite Srl
- Aadi Bioscience Inc
- AbbVie Inc
- ABL Bio Inc
- Acepodia Biotech Inc
- Actinium Pharmaceuticals Inc
- Active Biotech AB
- Adicet Bio Inc
- Aduro BioTech Inc
- Aeglea BioTherapeutics Inc
- Affimed GmbH
- Agenus Inc
- Allife Medical Science and Technology Co Ltd
- Allogene Therapeutics Inc
- Ambrx Inc
- Amgen Inc
- Anhui Anke Biotechnology (Group) Co Ltd
- Antengene Corp
- APIM Therapeutics AS
- APO-T BV
- Arcellx Inc
- Ariz Precision Medicine Inc
- Ascenta Therapeutics Inc
- Ascentage Pharma Group International
- Asclepius Technology Company Group Suzhou Co Ltd
- Aslan Pharmaceuticals Ltd
- AstraZeneca Plc
- Atara Biotherapeutics Inc
- Auransa Inc
- Aurigene Discovery Technologies Ltd
- Autolus Therapeutics Plc
- Ayala Pharmaceuticals Inc
- Bantam Pharmaceutical LLC
- Bayer AG
- Beijing Immunochina Medical Science & Technology Co Ltd
- Beijing Sunbio Biotech Co Ltd
- Bellicum Pharmaceuticals Inc
- Betta Pharmaceuticals Co Ltd
- BeyondSpring Inc
- BioLineRx Ltd
- Biomunex Pharmaceuticals
- Biosion Inc
- Biotest AG
- BioVec Pharma Inc
- BiVictriX Therapeutics Ltd
- Boehringer Ingelheim International GmbH
- Boryung ViGenCell Inc
- Boston Biomedical Inc
- Bristol-Myers Squibb Co
- CanBas Co Ltd
- Caribou Biosciences Inc
- CARsgen Therapeutics Ltd
- Cartesian Therapeutics Inc
- CASI Pharmaceuticals Inc
- CDR-Life Inc
- Cell Source Inc
- CellCentric Ltd
- Cellectar Biosciences Inc
- Cellectis SA
- Celleron Therapeutics Ltd
- Cellestia Biotech AG
- Cello Therapeutics Inc
- Cellular Biomedicine Group Inc
- Celularity Inc
- Celyad Oncology
- Centrax International Inc
- Cerecor Inc
- Checkpoint Therapeutics Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chipscreen Biosciences Ltd
- Chong Kun Dang Pharmaceutical Corp
- CiMaas BV
- Cleave Therapeutics Inc
- Constellation Pharmaceuticals Inc
- Corvus Pharmaceuticals Inc
- CRISPR Therapeutics AG
- CStone Pharmaceuticals Co Ltd
- Curis Inc
- Curocell Inc
- Cyclacel Pharmaceuticals Inc
- Cyteir Therapeutics Inc
- Cytonus Therapeutics Inc
- Cytovia Therapeutics Inc
- Daiichi Sankyo Co Ltd
- DC Prime BV
- DeuteRx LLC
- Diverse Biotech Inc
- Eli Lilly and Co
- Enceladus Pharmaceuticals BV
- EpicentRx Inc
- Epizyme Inc
- eTheRNA Immunotherapies NV
- Eureka Therapeutics Inc
- ExCellThera Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fera Pharmaceuticals LLC
- Fortis Therapeutics Inc
- Gadeta BV
- Galileo Research srl
- Gamida Cell Ltd
- GemoPharm
- Genenta Science srl
- Genentech Inc
- Genmab AS
- Geron Corp
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Gliknik Inc
- GlycoMimetics Inc
- Glycostem Therapeutics BV
- GlyTR Therapeutics Inc
- GP Pharm SA
- Gracell Biotechnology Ltd
- GT Biopharma Inc
- Guangdong Zhongsheng Pharmaceutical Co Ltd
- HaemaLogix Pty Ltd
- Harbour BioMed
- Harpoon Therapeutics Inc
- Hebei Senlang Biotechnology Inc Ltd
- Heidelberg Pharma AG
- Helix BioPharma Corp
- Helocyte Biosciences Inc
- Hengenix Biotech Inc
- Hinova Pharmaceuticals Inc
- HitGen LTD
- HRAIN Biotechnology Co Ltd
- Hunan Siweikang Therapeutics Ltd
- HuniLife Biotechnology Inc
- Hutchison MediPharma Ltd
- iCell Gene Therapeutics LLC
- Ichnos Sciences Inc
- IDAC Theranostics Inc
- IDP Discovery Pharma SL
- IGM Biosciences Inc
- ImmuneTarget Inc
- ImmunityBio Inc
- Immunomedics Inc
- Immunotech Biopharm Ltd
- Incuron LLC
- Incyte Corp
- Indapta Therapeutics Inc
- Inflection Biosciences Ltd
- Inmune Bio Inc
- Innovative Cellular Therapeutics Co Ltd
- Intra-Immusg Pvt Ltd
- Inven2 AS
- Inventiva
- IO Biotech ApS
- Ionis Pharmaceuticals Inc
- Ionova Life Science Co Ltd
- Istesso Ltd
- Iterion Therapeutics
- Janpix Inc
- Jiangsu Hengrui Medicine Co Ltd
- JN Biosciences LLC
- Johnson & Johnson
- JSK Therapeutics Inc
- Jubilant Therapeutics Inc
- Juno Therapeutics Inc
- Juventas Cell Therapy Ltd
- JW Pharmaceutical Corp
- Kangpu Biopharmaceuticals Ltd
- Karyopharm Therapeutics Inc
- Kiadis Pharma NV
- Kleo Pharmaceuticals Inc
- Klyss Biotech Inc
- Komipharm International Co Ltd
- Kymab Ltd
- Laekna Therapeutics Shanghai Co Ltd
- Leadiant Biosciences Inc
- Les Laboratoires Servier SAS
- Leukogene Therapeutics Inc
- Ligand Pharmaceuticals Inc
- Lokon Pharma AB
- Luye Pharma Group Ltd
- Mablink Bioscience
- Machavert Pharmaceuticals LLC
- Marker Therapeutics Inc
- Max Biopharma Inc
- MediGene AG
- MedPacto Inc
- Merck & Co Inc
- Merck KGaA
- Millennium Pharmaceuticals Inc
- Miltenyi Biotec GmbH
- MimiVax LLC
- Modulation Therapeutics Inc
- Molecular Partners AG
- Molecular Templates Inc
- MolMed SpA
- Momenta Pharmaceuticals Inc
- MorphoSys AG
- Multitude therapeutics Inc
- Mustang Bio Inc
- Mycovia Pharmaceuticals Inc
- Nanjing Bioheng Biotech Co Ltd
- Nanjing CART Medical Technology Co Ltd
- Nanjing Iaso Biotherapeutics Co Ltd
- Nanjing Legend Biotech Co Ltd
- NantKwest Inc
- Nektar Therapeutics
- Neonc Technologies Inc
- NewBay Medical Technology Co Ltd
- NexImmune Inc
- Northlake International LLC
- Novartis AG
- Noxxon Pharma AG
- Oncoceutics Inc
- Oncodesign SA
- OncoFusion Therapeutics Inc
- Oncolytics Biotech Inc
- Onconova Therapeutics Inc
- OncoPep Inc
- Oncopeptides AB
- OncoTartis Inc
- OncoTherapy Science Inc
- One World Cannabis Ltd
- Ono Pharmaceutical Co Ltd
- Origincell Technology Group Co Ltd
- Otsuka Pharmaceutical Co Ltd
- PentixaPharm GmbH
- Peptron Inc
- PersonGen Anke Cellular Therapeutics Co Ltd
- PersonGen Biomedicine Suzhou Co Ltd
- Pfizer Inc
- Pharma Mar SA
- Phi Pharma SA
- Phosplatin Therapeutics LLC
- PI Therapeutics Ltd
- Pimera Inc
- Poseida Therapeutics Inc
- Precision Biosciences Inc
- Prescient Therapeutics Ltd
- Protheragen Inc
- Quadriga BioSciences Inc
- Qwixel Therapeutics LLC
- Rainier Therapeutics Inc
- Rapa Therapeutics LLC
- RAPT Therapeutics Inc
- RedHill Biopharma Ltd
- Regeneron Pharmaceuticals Inc
- Rhizen Pharmaceuticals SA
- Samus Therapeutics LLC
- Sanofi
- Seattle Genetics Inc
- SELLAS Life Sciences Group Inc
- Senhwa Biosciences Inc
- Shanghai Bioray Laboratory Inc
- Shanghai Theorion Pharmaceutical Co Ltd
- Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shenogen Pharma Group Ltd
- Shuttle Pharmaceuticals Inc
- Sichuan Kelun Pharmaceutical Co Ltd
- SignalRx Pharmaceuticals Inc
- SignPath Pharma Inc
- Sorrento Therapeutics Inc
- SpecificiT Pharma Inc
- Spectrum Pharmaceuticals Inc
- Sphaera Pharma Pte Ltd
- SpringWorks Therapeutics Inc
- Starton Therapeutics Inc
- Sunomix Therapeutics
- Surface Oncology Inc
- Sutro Biopharma Inc
- Suzhou Maximum Bio-tech Co Ltd
- T-CURX GmbH
- T-Knife GmbH
- TaiGen Biotechnology Co Ltd
- Taiho Oncology Inc
- TaiRx Inc
- Takeda Pharmaceutical Co Ltd
- Targazyme Inc
- TeneoBio Inc
- Tiziana Life Sciences Plc
- Tmunity Therapeutics Inc
- Tolero Pharmaceuticals Inc
- Transgene Biotek Ltd
- Trillium Therapeutics Inc
- Triterpenoid Therapeutics Inc
- Ube Industries Ltd
- Vaccibody AS
- Vaxil Bio Therapeutics Ltd
- Vichem Chemie Research Ltd
- Visterra Inc
- Vycellix Inc
- Vyriad Inc
- WindMIL Therapeutics Inc
- Wugen Inc
- Wuhan Bio-Raid Biotechnology Co Ltd
- Wuhan YZY Biopharma Co Ltd
- XEME BioPharma Inc
- Xiangxue Life Sciences
- XNK Therapeutics AB
- Zhengda Tianqing Pharmaceutical Group Co Ltd
- Zovis Pharmaceuticals
